Общедоступные статьи - Maggie CheangПодробнее...
84 статьи доступны в некоторых источниках
Проверить
Supervised risk predictor of breast cancer based on intrinsic subtypes
JS Parker, M Mullins, MCU Cheang, S Leung, D Voduc, T Vickery, ...
Journal of clinical oncology 27 (8), 1160-1167, 2009
Финансирование: US National Institutes of Health
Проверить
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
MCU Cheang, SK Chia, D Voduc, D Gao, S Leung, J Snider, M Watson, ...
JNCI: Journal of the National Cancer Institute 101 (10), 736-750, 2009
Финансирование: US National Institutes of Health
Проверить
Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 …
FM Blows, KE Driver, MK Schmidt, A Broeks, FE Van Leeuwen, ...
PLoS medicine 7 (5), e1000279, 2010
Финансирование: US National Institutes of Health, Cancer Research UK
Проверить
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
I Garcia-Murillas, G Schiavon, B Weigelt, C Ng, S Hrebien, RJ Cutts, ...
Science translational medicine 7 (302), 302ra133-302ra133, 2015
Финансирование: Breast Cancer Now, UK, Cancer Research UK, National Institute for Health …
Проверить
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor–positive breast cancer
TO Nielsen, JS Parker, S Leung, D Voduc, M Ebbert, T Vickery, SR Davies, ...
Clinical cancer research 16 (21), 5222-5232, 2010
Финансирование: US National Institutes of Health
Проверить
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
A Tutt, H Tovey, MCU Cheang, S Kernaghan, L Kilburn, P Gazinska, ...
Nature medicine 24 (5), 628-637, 2018
Финансирование: US National Institutes of Health, Breast Cancer Now, UK, Cancer Research UK …
Проверить
Prognostic significance of progesterone receptor–positive tumor cells within immunohistochemically defined luminal A breast cancer
A Prat, MCU Cheang, M Martín, JS Parker, E Carrasco, R Caballero, ...
Journal of clinical oncology 31 (2), 203-209, 2013
Финансирование: US National Institutes of Health
Проверить
Molecular characterization of basal‐like and non‐basal‐like triple‐negative breast cancer
A Prat, B Adamo, MCU Cheang, CK Anders, LA Carey, CM Perou
The oncologist 18 (2), 123-133, 2013
Финансирование: US National Institutes of Health
Проверить
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial
J Hugh, J Hanson, MCU Cheang, TO Nielsen, CM Perou, C Dumontet, ...
Journal of clinical oncology 27 (8), 1168-1176, 2009
Финансирование: US National Institutes of Health
Проверить
Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus …
LA Carey, DA Berry, CT Cirrincione, WT Barry, BN Pitcher, LN Harris, ...
Journal of Clinical Oncology 34 (6), 542-549, 2016
Финансирование: US National Institutes of Health, Susan G. Komen
Проверить
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
LJ Esserman, DA Berry, MCU Cheang, C Yau, CM Perou, L Carey, ...
Breast cancer research and treatment 132, 1049-1062, 2012
Финансирование: US National Institutes of Health
Проверить
Use of mutation profiles to refine the classification of endometrial carcinomas
MK McConechy, J Ding, MCU Cheang, KC Wiegand, J Senz, AA Tone, ...
The Journal of pathology 228 (1), 20-30, 2012
Финансирование: US National Institutes of Health, Canadian Institutes of Health Research
Проверить
Defining breast cancer intrinsic subtypes by quantitative receptor expression
MCU Cheang, M Martin, TO Nielsen, A Prat, D Voduc, ...
The oncologist 20 (5), 474-482, 2015
Финансирование: US National Institutes of Health, Cancer Research UK
Проверить
based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study
A Prat, G Bianchini, M Thomas, A Belousov, MCU Cheang, A Koehler, ...
Clinical Cancer Research 20 (2), 511-521, 2014
Финансирование: Cancer Research UK
Проверить
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label …
I Smith, J Robertson, L Kilburn, M Wilcox, A Evans, C Holcombe, ...
The Lancet Oncology 21 (11), 1443-1454, 2020
Финансирование: Cancer Research UK, National Institute for Health Research, UK
Проверить
Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases
AB Rajput, DA Turbin, MCU Cheang, DK Voduc, S Leung, KA Gelmon, ...
Breast cancer research and treatment 107, 249-257, 2008
Финансирование: Canadian Institutes of Health Research
Проверить
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer
F Brasó-Maristany, S Filosto, S Catchpole, R Marlow, J Quist, ...
Nature medicine 22 (11), 1303-1313, 2016
Финансирование: US National Institutes of Health, UK Biotechnology and Biological Sciences …
Проверить
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2
GC Wishart, CD Bajdik, E Dicks, E Provenzano, MK Schmidt, M Sherman, ...
British journal of cancer 107 (5), 800-807, 2012
Финансирование: US National Institutes of Health, Cancer Research UK
Проверить
Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor–positive early breast cancer: PALLET trial
S Johnston, S Puhalla, D Wheatley, A Ring, P Barry, C Holcombe, ...
Journal of Clinical Oncology 37 (3), 178-189, 2019
Финансирование: Cancer Research UK, National Institute for Health Research, UK
Проверить
Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy
A Prat, C Fan, A Fernández, KA Hoadley, R Martinello, M Vidal, M Viladot, ...
BMC medicine 13, 1-11, 2015
Финансирование: US National Institutes of Health, Government of Spain, Susan G. Komen
Информация о публикациях и финансировании собрана автоматически.